Table 3 The changes (∆) of clinical parameters from baseline to week 2 in different outcomes and treatment groups
All | Survival | Mortality | p | Telbivudine | Entecavir | p | |
|---|---|---|---|---|---|---|---|
Patient no | 21 | 17 | 4 | 9 | 12 | ||
ALT | −1161 (−2313-+106) | −1161 (−2313-+106) | −890 (−2057- -44) | 1.000 | −1383 (−2313-+106) | −547.5 (−2057- -30) | 0.256 |
Bilirubin T | −0.4 (−9.1-+12.2) | −1.2 (−9.1-+11.5) | 8.05 (5.9-12.2) | 0.009 | −0.9 (−6-+11.5) | −0.3 (−9.1-+12.2) | 0.722 |
Creatinine | 0.22 (−0.1-+2.33) | 0.08 (−0.10-+0.87) | 0.49 (0.23-2.33) | 0.049 | 0.22 (−0.09-+0.87) | 0.27 (−0.1-+2.33) | 0.594 |
eGFR | |||||||
MDRD | −23 (−162-+58) | −16 (−72-+58) | −85.5 (−162- -36) | 0.008 | −23 (−99-+23) | −23 (−162-+58) | 0.749 |
CKD-EPI | −16.1 (−65.2-+12.6) | −6.0 (−65.2-+12.6) | −35.5 (−51.3- -21.7) | 0.049 | −21.1 (−65.2-+6.81) | −13.0 (−51.3-+12.6) | 0.776 |
INR | −0.3 (−1.0-+0.9) | −0.3 (−1.0-+0.9) | −0.4 (−0.5-+0.7) | 0.318 | −0.3 (−0.6-+0.9) | −0.3 (−1.0-+0.7) | 0.971 |
AFP | 151.5 (−140.7-+2326.6) | 184.2 (−110.2-+2326.6) | −73.2 (−140.7- -5.8) | 0.057 | 184.2 (−5.8-+1385.9) | 101.2 (−140.7-+2326.6) | 0.386 |
HBV DNA (log10 cps/ml) | −3.27 (−5.47- -0.55) | −3.4 (−5.5- -0.6) | −1.4 (−1.8- -1.0) | 0.074 | −3.4 (−5.0- -1.0) | −3.0 (−5.5- -0.6) | 0.922 |
MELD score | −1.0 (−11-+14) | −1.0 (−11-+14) | 0.0 (−1-+12) | 0.344 | −1.0 (−6-+14) | −0.5 (−11-+12) | 0.775 |